Alterations in nicotinic α4β2 receptor binding in vascular dementia using 123I-5IA-85380 SPECT: Comparison with regional cerebral blood flow

Neurobiology of Aging

Volumn 32, Issue 2, 2011, Pages 293-301

  Colloby, S J ^a   Firbank, M J ^a   Pakrasi, S ^a   Perry, E K ^a   Pimlott, S L ^b   Wyper, D J ^c   McKeith, I G ^a   Williams, E D ^d   O'Brien, J T ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^d SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

Nicotinic; SPECT; SPM; Vascular dementia

Indexed keywords

5 IODO 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CAUDATE NUCLEUS; CHOLINERGIC ACTIVITY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DEPRESSION; DRUG UPTAKE; FEMALE; HALLUCINATION; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

AGED; AGED, 80 AND OVER; AZETIDINES; BLOOD CIRCULATION TIME; BRAIN MAPPING; BUTANONES; CEREBROVASCULAR CIRCULATION; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78649871327     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.005     Document Type: Article

References (46)

1. Acton P.D., Friston K.J. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur. J. Nucl. Med. Mol. Imag. 1998, 25(7):663-667.
2. Babikian V., Ropper A.H. Binswanger's disease: a review. Stroke 1987, 18(1):2-12.
3. Behrens T.E., Johansen-Berg H., Woolrich M.W., Smith S.M., Wheeler-Kingshott C.A., Boulby P.A., Barker G.J., Sillery E.L., Sheehan K., Ciccarelli O., Thompson A.J., Brady J.M., Matthews P.M. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat. Neurosci. 2003, 6(7):750-757.
4. Brett, M., 1999. The MNI brain and the Talairach Atlas. MRC Cognition and Brain Sciences Unit. http://www.mrc-cbu.cam.ac.uk/Imaging/contents.html.
5. Brett M., Anton J.-L., Valabregue R., Poline J.B. Region of interest analysis using an SPM toolbox. Neuroimage 2002, 6(2).
6. Brett M., Leff A.P., Rorden C., Ashburner J. Spatial normalization of brain images with focal lesions using cost function masking. Neuroimage 2001, 14(2):486-500.
7. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol. Psychiatry 2001, 49(3):175-184.
8. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., Kerwin R., Perry R., Perry E. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J. Neurochem. 1999, 73(4):1590-1597.
9. Court J.A., Piggott M.A., Lloyd S., Cookson N., Ballard C.G., McKeith I.G., Perry R.H., Perry E.K. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000, 98(1):79-87.
10. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44(12):2308-2314.
11. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002, 359(9314):1283-1290.
12. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 1975, 12(3):189-198.
13. Frackowiak R.S., Friston K.J., Frith C.D., Dolan R.J., Mazziotta J.C. Human Brain Function 1997, Academic Press, London. First ed.
14. Friston K.J., Worsley K.J., Frackowiak R.S.J., Mazziotta J.C., Evans A.C. Assessing the significance of focal activations using their spatial extent. Hum. Brain Map. 1994, 1(1):214-220.
15. Fujita M., Ichise M., Zoghbi S.S., Liow J.S., Ghose S., Vines D.C., Sangare J., Lu J.Q., Cropley V.L., Iida H., Kim K.M., Cohen R.M., Bara-Jimenez W., Ravina B., Innis R.B. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann. Neurol. 2006, 59(1):174-177.
16. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia 1994, 5(3-4):163-167.
17. Hanyu H., Shimuzu S., Tanaka Y., Takasaki M., Koizumi K., Abe K. Cerebral blood flow patterns in Binswanger's disease: a SPECT study using three-dimensional stereotactic surface projections. J. Neurol. Sci. 2004, 220(1-2):79-84.
18. Johansen-Berg H., Behrens T.E., Sillery E., Ciccarelli O., Thompson A.J., Smith S.M., Matthews P.M. Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb. Cortex 2005, 15(1):31-39.
19. Jones S., Sudweeks S., Yakel J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 1999, 22(12):555-561.
20. Kadir A., Almkvist O., Wall A., Langstrom B., Nordberg A. PET imaging of cortical (11)C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl.) 2006, 188(4):509-520.
21. Kerrouche N., Herholz K., Mielke R., Holthoff V., Baron J.C. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. J. Cereb. Blood Flow. Metab. 2006, 26(9):1213-1221.
22. Le Novere N., Changeux J.P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mol. Evol. 1995, 40(2):155-172.
23. Lindstrom J., Anand R., Peng X., Gerzanich V., Wang F., Li Y. Neuronal nicotinic receptor subtypes. Ann. N. Y. Acad. Sci. 1995, 757:100-116.
24. Martin-Ruiz C., Court J., Lee M., Piggott M., Johnson M., Ballard C., Kalaria R., Perry R., Perry E. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol. Scand. Suppl. 2000, 176:34-41.
25. Mitsis E.M., Cosgrove K.P., Staley J.K., Bois F., Frohlich E.B., Tamagnan G.D., Estok K.M., Seibyl J.P., van Dyck C.H. Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2007.12.008.
26. Nagata K., Maruya H., Yuya H., Terashi H., Mito Y., Kato H., Sato M., Satoh Y., Watahiki Y., Hirata Y., Yokoyama E., Hatazawa J. Can PET data differentiate Alzheimer's disease from vascular dementia?. Ann. N. Y. Acad. Sci. 2000, 903:252-261.
27. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 1995, 9(1):21-27.
28. O'Brien J.T., Colloby S.J., Pakrasi S., Perry E.K., Pimlott S.L., Wyper D.J., McKeith I.G., Williams E.D. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J. Neurol. Neurosurg. Psychiatry 2007, 78(4):356-362.
29. O'Brien J.T., Colloby S.J., Pakrasi S., Perry E.K., Pimlott S.L., Wyper D.J., McKeith I.G., Williams E.D. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using (123)I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 2008, 40(3):1056-1063.
30. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., Bowler J.V., Ballard C., DeCarli C., Gorelick P.B., Rockwood K., Burns A., Gauthier S., DeKosky S.T. Vascular cognitive impairment. Lancet Neurol. 2003, 2(2):89-98.
31. Perry E., Ziabreva I., Perry R., Aarsland D., Ballard C. Absence of cholinergic deficits in "pure" vascular dementia. Neurology 2005, 64(1):132-133.
32. Perry E.K., Haroutunian V., Davis K.L., Levy R., Lantos P., Eagger S., Honavar M., Dean A., Griffiths M., McKeith I.G., et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994, 5(7):747-749.
33. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., Perry R.H., Perry E.K., Wyper D. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004, 29(1):108-116.
34. Ray M., Bohr I., McIntosh J.M., Ballard C., McKeith I., Chalon S., Guilloteau D., Perry R., Perry E., Court J.A., Piggott M. Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci. Lett. 2004, 372(3):220-225.
35. Rinne J.O., Myllykyla T., Lonnberg P., Marjamaki P. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 1991, 547(1):167-170.
36. Roman G.C. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol. Scand. Suppl. 2002, 178:6-9.
37. Roman G.C., Wilkinson D.G., Doody R.S., Black S.E., Salloway S.P., Schindler R.J. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord. 2005, 20(6):338-344.
38. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., Goddard R. CAMDEX a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br. J. Psychiatry 1986, 149:698-709.
39. Shim Y.S., Yang D.W., Kim B.S., Shon Y.M., Chung Y.A. Comparison of regional cerebral blood flow in two subsets of subcortical ischemic vascular dementia: statistical parametric mapping analysis of SPECT. J. Neurol. Sci. 2006, 250(1-2):85-91.
40. Sihver W., Gillberg P.G., Svensson A.L., Nordberg A. Autoradiographic comparison of [3H](-)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. Neuroscience 1999, 94(3):685-696.
41. Sultzer D.L., Mahler M.E., Cummings J.L., Van Gorp W.G., Hinkin C.H., Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. Arch. Neurol. 1995, 52(8):773-780.
42. Tomimoto H., Ohtani R., Shibata M., Nakamura N., Ihara M. Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement. Geriatr. Cogn. Disord. 2005, 19(5-6):282-288.
43. Walker M.P., Ayre G.A., Cummings J.L., Wesnes K., McKeith I.G., O'Brien J.T., Ballard C.G. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br. J. Psychiatry 2000, 177:252-256.
44. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J., Kertesz A., Pratt R.D. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003, 61(4):479-486.
45. Yang D.W., Kim B.S., Park J.K., Kim S.Y., Kim E.N., Sohn H.S. Analysis of cerebral blood flow of subcortical vascular dementia with single photon emission computed tomography: adaptation of statistical parametric mapping. J. Neurol. Sci. 2002, 203-204:199-205.
46. Yoshikawa T., Murase K., Oku N., Kitagawa K., Imaizumi M., Takasawa M., Nishikawa T., Matsumoto M., Hatazawa J., Hori M. Statistical image analysis of cerebral blood flow in vascular dementia with small-vessel disease. J. Nucl. Med. 2003, 44(4):505-511.